$OGI

Organigram Global Inc. (OGI) accelerated the integration of Sanity Group, aligning leadership and operations. Sanity contributed CAD 40 million (35% of revenue) in the last quarter, with revenue growing 34% to €25.5 million. The company amended the earnout agreement, fixing it at 85% of the maximum value, with €20 million in cash and €76 million in shares payable in 2027. New leadership roles were appointed to support global growth.

Organigram (OGI) reported Q3 2026 revenue of $105.8M, up 49% YoY, driven by Sanity Group acquisition. Adjusted EBITDA rose 136% to $13.4M. International sales now 35% of total revenue. CEO Yamanaka highlighted strategic transformation and record THC potency. CFO Guyatt expects margins to exceed fiscal 2025 levels. The company faces EU supply constraints and U.S. regulatory uncertainty.

Organigram Global Inc. reported Q3 2026 record net revenue and adjusted EBITDA, citing Sanity Group’s first consolidation and Canada operational efficiencies. International revenue rose to about 35% of total. It reiterated FY2026 revenue guidance above $350 million and expects Q4 positive free cash flow. Net income was $105.5 million, including $105.8 million fair value gains.

Simply Wall St reports Organigram Global (TSX:OGI) shares were up about 23% before its Q3 release, trading near CA$1.69 with a trailing P/E of 2.7x. Q3 revenue rose to CA$105.8m from CA$70.8m and net income to CA$105.5m from a CA$6.3m loss. Management guided FY2026 revenue above CA$350m, while free cash flow stayed negative.

Organigram Global Inc. (OGI) reported Q3 fiscal 2026 results for the quarter ended June 30, 2026. The company said gross revenue rose to $145.1 million (+32% YoY), net revenue to $105.8 million (+49%), and adjusted EBITDA to $13.4 million (+136%). It cited Sanity Group’s acquisition contribution and noted a TSX share-price gain in early trading.

Organigram Global Inc. (OGI) shares rose about 10.95% on Aug. 11, 2026, as investors focused on the company’s Sanity Group acquisition and expectations for cannabis market growth. The article cites quarterly revenue of about $59.8M, gross margin near 31.9%, and free cash flow around -$7.0M, with first consolidated results expected in August 2026.

OrganiGram (OGI) reported Q3 adjusted EPS loss of $0.05 per share, wider than the Zacks Consensus loss of $0.01, while revenue rose to $76.41 million, 12.95% above estimates. Year-ago revenue was $51.16 million. The article cites a Zacks Rank #3 (Hold) and notes consensus outlook of $0.01 EPS on $79.35 million revenue next quarter.

Curaleaf Holdings (CURA-T) announced a hostile bid for Aurora Cannabis (ACB-T) valuing the offer at US$4 per Aurora share, including 0.3463 Curaleaf shares and US$0.75 cash, a 45% premium to 30-day VWAP. Other updates: Pet Valu (PET-T) Q2 revenue $290.7M and beat; Organigram (OGI-T) Q3 revenue $105.8M beat; Cineplex (CGX-T) mixed; H&R REIT (HR-UN-T) to sell GO Residential REIT (GO-U-T) for about $6.7B; Cargojet (CJT-T) Q2 revenue $275.8M beat, adjusted EPS miss.

Organigram Global Inc. reported Q3 fiscal 2026 results for the quarter and nine months ended June 30, 2026, saying net revenue rose and it swung to net income, according to the company’s earnings release and call on Aug. 11, 2026. The stock was up sharply on the day.

Organigram Global Inc. reported Q3 ended June 30, 2026 net revenue of $105.8 million, up 49% from $70.8 million, and adjusted EBITDA of $13.4 million, up from $5.7 million. Net income swung to $105.5 million from a $6.3 million loss, helped by non-cash preferred share fair value gains. The company cited Sanity Group integration and guided FY2026 net revenue above $350 million.